Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1

Chi Chung Wang, Meng Feng Tsai, Ting Hao Dai, Tse-Ming Hong, Wing Kai Chan, Jeremy J.W. Chen, Pan Chyr Yang

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. However, the mechanism of HLJ1 activation is currently unclear. Here, we identify an enhancer segment in the HLJ1 gene at -2,125 to -1,039 bp upstream of the transcription start site. A 50-bp element between -1,492 and -1,443 bp is the minimal enhancer segment, which includes the activator protein 1 (AP-1) site (-1,457 to -1,451 bp), an essential regulatory domain that binds the transcriptional factors FosB, JunB, and JunD. Chromatin immunoprecipitation assays confirm that these AP-1 family members bind to a specific site in the HLJ1 enhancer segment in vivo. Overexpression of either YY1 at promoter or AP-1 at enhancer results in a 3-fold increase in the transcriptional activity of HLJ1. We propose a novel mechanism whereby expression of the tumor suppressor, HLJ1, is upregulated via enhancer AP-1 binding to promoter YY1 and the coactivator, p300, through DNA bending and multiprotein complex formation. The combined expression of AP-1 and YY1 enhances HLJ1 expression by more than five times and inhibits in vitro cancer cell invasion. Elucidation of the regulatory mechanism of HLJ1 expression may facilitate the development of personalized therapy by inhibiting cancer cell proliferation, angiogenesis, and metastasis.

Original languageEnglish
Pages (from-to)4816-4826
Number of pages11
JournalCancer Research
Volume67
Issue number10
DOIs
Publication statusPublished - 2007 May 15

Fingerprint

YY1 Transcription Factor
Transcription Factor AP-1
Neoplasms
Neoplasm Metastasis
Multiprotein Complexes
Chromatin Immunoprecipitation
Transcription Initiation Site
Protein Binding
Carcinogenesis
Cell Proliferation
DNA
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Wang, Chi Chung ; Tsai, Meng Feng ; Dai, Ting Hao ; Hong, Tse-Ming ; Chan, Wing Kai ; Chen, Jeremy J.W. ; Yang, Pan Chyr. / Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. In: Cancer Research. 2007 ; Vol. 67, No. 10. pp. 4816-4826.
@article{4543aa41c69a437f84637104dfec63d7,
title = "Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1",
abstract = "HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. However, the mechanism of HLJ1 activation is currently unclear. Here, we identify an enhancer segment in the HLJ1 gene at -2,125 to -1,039 bp upstream of the transcription start site. A 50-bp element between -1,492 and -1,443 bp is the minimal enhancer segment, which includes the activator protein 1 (AP-1) site (-1,457 to -1,451 bp), an essential regulatory domain that binds the transcriptional factors FosB, JunB, and JunD. Chromatin immunoprecipitation assays confirm that these AP-1 family members bind to a specific site in the HLJ1 enhancer segment in vivo. Overexpression of either YY1 at promoter or AP-1 at enhancer results in a 3-fold increase in the transcriptional activity of HLJ1. We propose a novel mechanism whereby expression of the tumor suppressor, HLJ1, is upregulated via enhancer AP-1 binding to promoter YY1 and the coactivator, p300, through DNA bending and multiprotein complex formation. The combined expression of AP-1 and YY1 enhances HLJ1 expression by more than five times and inhibits in vitro cancer cell invasion. Elucidation of the regulatory mechanism of HLJ1 expression may facilitate the development of personalized therapy by inhibiting cancer cell proliferation, angiogenesis, and metastasis.",
author = "Wang, {Chi Chung} and Tsai, {Meng Feng} and Dai, {Ting Hao} and Tse-Ming Hong and Chan, {Wing Kai} and Chen, {Jeremy J.W.} and Yang, {Pan Chyr}",
year = "2007",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-07-0504",
language = "English",
volume = "67",
pages = "4816--4826",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. / Wang, Chi Chung; Tsai, Meng Feng; Dai, Ting Hao; Hong, Tse-Ming; Chan, Wing Kai; Chen, Jeremy J.W.; Yang, Pan Chyr.

In: Cancer Research, Vol. 67, No. 10, 15.05.2007, p. 4816-4826.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1

AU - Wang, Chi Chung

AU - Tsai, Meng Feng

AU - Dai, Ting Hao

AU - Hong, Tse-Ming

AU - Chan, Wing Kai

AU - Chen, Jeremy J.W.

AU - Yang, Pan Chyr

PY - 2007/5/15

Y1 - 2007/5/15

N2 - HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. However, the mechanism of HLJ1 activation is currently unclear. Here, we identify an enhancer segment in the HLJ1 gene at -2,125 to -1,039 bp upstream of the transcription start site. A 50-bp element between -1,492 and -1,443 bp is the minimal enhancer segment, which includes the activator protein 1 (AP-1) site (-1,457 to -1,451 bp), an essential regulatory domain that binds the transcriptional factors FosB, JunB, and JunD. Chromatin immunoprecipitation assays confirm that these AP-1 family members bind to a specific site in the HLJ1 enhancer segment in vivo. Overexpression of either YY1 at promoter or AP-1 at enhancer results in a 3-fold increase in the transcriptional activity of HLJ1. We propose a novel mechanism whereby expression of the tumor suppressor, HLJ1, is upregulated via enhancer AP-1 binding to promoter YY1 and the coactivator, p300, through DNA bending and multiprotein complex formation. The combined expression of AP-1 and YY1 enhances HLJ1 expression by more than five times and inhibits in vitro cancer cell invasion. Elucidation of the regulatory mechanism of HLJ1 expression may facilitate the development of personalized therapy by inhibiting cancer cell proliferation, angiogenesis, and metastasis.

AB - HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis and cancer metastasis. However, the mechanism of HLJ1 activation is currently unclear. Here, we identify an enhancer segment in the HLJ1 gene at -2,125 to -1,039 bp upstream of the transcription start site. A 50-bp element between -1,492 and -1,443 bp is the minimal enhancer segment, which includes the activator protein 1 (AP-1) site (-1,457 to -1,451 bp), an essential regulatory domain that binds the transcriptional factors FosB, JunB, and JunD. Chromatin immunoprecipitation assays confirm that these AP-1 family members bind to a specific site in the HLJ1 enhancer segment in vivo. Overexpression of either YY1 at promoter or AP-1 at enhancer results in a 3-fold increase in the transcriptional activity of HLJ1. We propose a novel mechanism whereby expression of the tumor suppressor, HLJ1, is upregulated via enhancer AP-1 binding to promoter YY1 and the coactivator, p300, through DNA bending and multiprotein complex formation. The combined expression of AP-1 and YY1 enhances HLJ1 expression by more than five times and inhibits in vitro cancer cell invasion. Elucidation of the regulatory mechanism of HLJ1 expression may facilitate the development of personalized therapy by inhibiting cancer cell proliferation, angiogenesis, and metastasis.

UR - http://www.scopus.com/inward/record.url?scp=34250376736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250376736&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0504

DO - 10.1158/0008-5472.CAN-07-0504

M3 - Article

VL - 67

SP - 4816

EP - 4826

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -